Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.

Smith, Christopher R; Kulyk, Svitlana; Ahmad, Misbha Ud Din; Arkhipova, Valentina; Christensen, James G; Gunn, Robin J; Ivetac, Anthony; Ketcham, John M; Kuehler, Jon; Lawson, J David; Thomas, Nicole C; Wang, Xiaolun; Marx, Matthew A.

Smith CR; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Kulyk S; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Ahmad MUD; ZoBio BV J. H. Oortweg 19 2333 CH Leiden Netherlands.
Arkhipova V; ZoBio BV J. H. Oortweg 19 2333 CH Leiden Netherlands.
Christensen JG; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Gunn RJ; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Ivetac A; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Ketcham JM; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Kuehler J; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Lawson JD; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Thomas NC; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Wang X; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Marx MA; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.

RSC Med Chem ; 13(12): 1549-1564, 2022 Dec 14.

Article en En | MEDLINE | ID: mdl-36545438

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article